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Abstract: The aim of our study was to understand the complex relationship between the major 
reproductive life events in women with Alzheimer’s disease. In a retrospective, case-control 
study, 275 women with Alzheimer’s disease (AD) and 276 control patients from a hospital 
population were enrolled from July 2007 to December 2010. The AD patients presented with later 
menopause (P , 0.01), lower occurrence of surgical menopause (P , 0.04), reduced hormone-
replacement therapy intake (P , 0.0001), and a longer reproductive life span (P , 0.01), 
compared to controls. No significant differences were found with respect to age at puberty, 
number of pregnancies, previous abortions, or contraceptive therapy. A higher education level 
appeared to have a protective role against the risk of developing AD. In women, menopause and 
hormone-replacement therapy can differentially modulate the clinical manifestations of AD, 
but these factors do not play a predictive role in its development.
Keywords: Alzheimer’s disease, gender, menopause, hormone-replacement therapy, surgical 
menopause, education
Introduction
In recent years, considerable attention has been focused on the effect of gender on 
cognitive functions and the development of neurodegenerative disorders. It is well 
known that sex steroids, particularly estrogen, act on the central nervous system to 
influence neurotransmission and synaptic plasticity and to protect the central nervous 
system from a wide range of neurotoxic insults.1
A higher prevalence of Alzheimer’s disease (AD) in women than in men has been 
reported, at least in European studies.2 Various factors, including fewer comorbid 
diseases in women and the consequent increase in life expectancy3,4 have been sug-
gested to explain this gender difference. In particular, the loss of the protective effects 
of estrogen in women after menopause, which has been demonstrated in vitro and 
in vivo,1–5 has been suggested as playing a role in the higher incidence of AD in women. 
However, studies on the effects of hormone-replacement therapy (HRT) on cognition 
(both as a prevention and as a therapy for AD) have produced controversial results,1–6 
and some studies have even suggested an increased risk of dementia in women using 
HRT.5–7 Some researchers5,6,8–10 have hypothesized that there may be a “critical period” 
around menopause during which the administration of HRT may reduce the risk of 
developing AD later in life; this effect seems to be more significant in women under 
49 years old.7,8 Other studies, however, have failed to detect the presence of this so-
called window of opportunity. The duration of HRT seems to significantly affect the 
outcome, as positive effects were mainly seen in short-term studies (,4 months).11 
Nonetheless, HRT should not be initiated in older women.8,12,13
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Undoubtedly, as compared to men, women experience 
increased cognitive vulnerability linked to endocrine 
fluctuations during their reproductive years.6 The menopausal 
transition is a particularly critical phase of cognitive 
vulnerability. Data from the literature suggest that natural 
menopause is not accompanied by substantial changes 
in cognitive abilities, although some studies suggest that 
women with later menopause have higher cognition.13,14 
At any rate, when postmenopausal deficits occur, they 
usually affect cognitive speed and concentration; however, 
these impairments mainly reflect premenopausal, reduced 
cognitive efficiency rather than being a direct consequence 
of menopause.14 Moreover, in some women, a complex 
relationship exists among mood, memory, and hormones, 
which may negatively influence attention-mediated 
cognitive functions.15,16 Additionally, when surgical 
menopause occurs early, women may have a higher risk of 
developing cognitive deficits, particularly those affecting 
verbal episodic memory.13–17 However, the occurrence of 
an unfavorable biological milieu, which may be genetically 
determined, predisposes women to an increased risk of 
neurodegeneration.18
Taken together, these data suggest that the complex 
interactions among genetic predisposition, comorbidities, 
and biological and environmental factors that promote the 
development of AD are further influenced by the presence 
of hormonal fluctuations in women.
The scientif ic literature’s main focus has been the 
influence of HRT and menopause on the occurrence of AD; 
the aim of this study was to further our understanding of 
the complex relationship between gender and dementia, 
considering all the major reproductive life events in women. 
In our analysis, besides reproductive life events, we also 
considered those factors known to be related to dementia 
(arterial hypertension, diabetes, cardiovascular diseases, and 
thyroid pathologies).19
Materials and methods
Subjects
Female outpatients with AD (diagnosed in accordance with 
the NINCDS-ADRDA criteria20) who were referred between 
July 2007 and December 2010 to the Alzheimer Assessment 
Unit at the C Mondino Institute of Neurology Foundation in 
Pavia, Italy and to the Department of Neurology, Ospedale 
di Circolo, Varese, Italy were included in this retrospective 
study. The diagnostic evaluation included an objective neuro-
logical examination, a neuropsychological examination, and 
neuroimaging (computed tomography or magnetic resonance 
imaging). The control sample was composed of women aged 
50 or more who were referred as outpatients to the same 
hospitals for noncognitive neurological complaints, includ-
ing peripheral nervous system diseases, motor disturbances, 
anxiety, and headache. Patients with Parkinson’s disease or 
cerebrovascular lesions (evidence of objective neurological 
signs and/or presence of neuroradiological correlates) were 
excluded. Therefore, the two groups of patients shared the 
same probability of admittance to the local health clinics for 
neurological problems. Additionally, the controls and the AD 
patients showed the same social and geographical distribu-
tion. The entire population, that is, both the AD patients and 
the controls, were menopausal.
Measures
All subjects underwent a structured interview for the 
collection of demographic and clinical characteristics. The 
following clinical parameters were considered: (1) family 
history of dementia; (2) age at puberty; (3) number 
of pregnancies; (4) previous abortions; (5) hormonal 
contraceptive therapy (at least 6 months); (6) age at 
menopause and type of menopause (physiological/surgical); 
(7) HRT (at least 6 months); (8) arterial hypertension; 
(9) diabetes; (10) cardiovascular diseases; (11) thyroid 
pathologies; (12) obesity; (13) reproductive system 
pathologies; (14) psychiatric diseases; (15) other pathologies 
(rheumatic, orthopedic, and endocrine [except thyroid] 
pathologies, among others); and (16) drug intake (classified 
as nonsteroidal anti-inflammatory drugs, anxiolytics, 
antidepressants, and neuroleptics, among others).
Conditions known to be related to dementia, such as 
arterial hypertension, diabetes, cardiovascular diseases, and 
thyroid pathologies (items 8–11, above), were considered 
separately from other pathological disorders that were 
clustered in item 15. For items 8 through 16, the onset before 
or after menopause was considered; for item 16, for AD 
patients, we considered only drug intake that occurred before 
disease onset. The difference between age at menopause and 
age at puberty was calculated, and termed “reproductive life 
span.”
Patients’ data were collected, with the caregivers’ 
participation when needed. Where, despite the additional 
information of caregivers, information gaps remained, the 
patients were excluded from the study.
The Mini-Mental State Examination (MMSE)21 (Italian 
version22) was administered to AD patients and controls to 
obtain a global cognitive evaluation. AD patients were also 
examined using the following measures: the Activities of Daily 
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Living23 scale to evaluate basic everyday activities (scores 
ranged from 0 to 6 – a higher score corresponded to a higher 
autonomy level); the Instrumental Activities of Daily Living24 
scale to evaluate more-complex activities (scores ranged from 
0 to 8 – a higher score corresponded to a higher autonomy 
level); the Neuropsychiatric Inventory25 to evaluate the presence 
and severity of behavioral disturbances (scores ranged from 
0 to 144, with higher scores indicating greater behavioral 
disturbances); and the Clinical Dementia Rating26 to evaluate 
disease severity (scores ranged from 0, which represented a lack 
of dementia, to 3, which represented severe dementia).
Statistical analysis
The data describing the frequency and dispersion of the quan-
titative and qualitative variables, respectively, were submitted 
to univariate comparisons using the χ2 test for the discrete 
variables and analysis of variance (ANOVA) for the continu-
ous variables. A multivariate comparison was performed with 
a regression model, including all the personnel and clinic 
variables related to the central investigation (reproductive 
life events) and those significantly different between the 
AD patients and the controls from the univariate analysis. 
The critical value for statistical significance was set at 0.05. 
All analyses were conducted using SPSS version 17.0 for 
Microsoft Windows® (SPSS Inc, Chicago, IL).
The study was carried out in accordance with the code 
of ethics of the World Medical Association (Declaration of 
Helsinki).
Results
Two hundred and seventy-f ive women with AD and 
276 controls were enrolled in this study. Another 35 patients 
in both centers were excluded because anamnestic 
information was missing; these subjects did not differ 
in age or schooling. The ratio of AD patients to control 
patients was similar between the two clinics (Pavia clinic: 
159:161; Varese clinic: 116:115); however, the age of the 
control patients at inclusion was lower for the Pavia clinic 
(P , 0.05).
The main clinical and demographic characteristics 
of the patients are reported in Table 1. The controls were 
significantly more educated than the AD patients (P , 0.02), 
while more AD patients had a family history of dementia 
(P , 0.0001). As expected, the MMSE mean score was 
significantly lower for AD patients (P , 0.0001).
With respect to the major reproductive life events, the 
control subjects went through early menopause (,45 years) 
more frequently than the AD patients did (P , 0.01). 
Additionally, the controls had a higher occurrence of surgical 
menopause (P , 0.04), a greater HRT intake (P , 0.0001), 
and a shorter reproductive life span (P , 0.01). No significant 
differences were found with respect to age at puberty, number 
of pregnancies, prior abortions, or contraceptive therapy 
(Table 2).
We evaluated the presence of other pathological 
conditions (items 8 through 16) in both groups and their onset 
with respect to menopause (either pre- or postmenopausal); 
(Table 3). The control patients had a higher frequency 
of other pathologies (item 15) and a greater drug intake 
(regardless of the type of drug) as compared to the demented 
patients (P , 0.0001); however, no differences were detected 
with respect to the onset of these pathologies. Although 
no differences were found with respect to reproductive 
system pathologies between AD patients and controls, 
Table 1 Clinical data and demographic characteristics of the AD and control patients (mean ± standard deviation)
AD patients (275) Controls (276) Significance df P
Age (range) 77.6 ± 6.3 (53–96) 76.7 ± 7.5 (52–91) 2.33a 1 0.124
Schooling (years) 6.1 ± 2.9 6.7 ± 3.2 5.32a 1 0.02
Family history for dementia (yes/no) 98/177 61/215 11.642b 0.0001
Age at disease onset (years) 74.7 ± 6.2 –
Early-onset AD (#65 years), n (%) 18 (6.5) –
Late-onset AD (.65 years), n (%) 257 (93.5) –
Disease duration (range) 2.9 ± 1.6 (1–10) –
CDR 1.6 ± 0.6 –
MMSE (range) 18.0 ± 3.3 (9–24) 27.9 ± 1.3 (25–30) 21.49a 1 0.0001
ADL 5.1 ± 1.1 –
IADL 3.8 ± 1.9 –
NPI 4.6 ± 3.3 –
Notes: aANOVA; bχ2 test.
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination; ADL, Activities of Daily Living; 
IADL, Instrumental Activities of Daily Living; NPI, Neuropsychiatric Inventory; df, degrees of freedom.
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the latter showed a higher occurrence of reproductive system 
pathologies before menopause (P , 0.02).
We considered the effects of different categories of 
drugs separately. We selected two specific types of drugs for 
further analysis: nonsteroidal anti-inflammatory drugs and 
psychotropic drugs (including anxiolytics, antidepressants, 
and neuroleptics), as they were the most frequently used. 
The use of these drugs was significantly more frequent in the 
controls than in the AD patients (P , 0.0001), irrespective 
of the type of drug. When we considered the onset of AD 
before or after menopause, only psychotropic drug intake 
before menopause was more frequent in the controls than in 
the AD patients (P , 0.0001). We did not separately consider 
the different types of pathologies, as the subgroups were too 
small to allow performing a statistical analysis.
Although we distinguished between early- and late-onset 
AD patients, only 18 (6.5%) patients had an early onset of the 
disease (before 45 years); so statistical analysis to evaluate 
the impact of hormonal exposure on the risk of developing 
AD was not performed.
We then constructed a multivariate regression model, 
in which the dependent variable was the status of patient 
or control and the independent variables were the clinic 
attended, the level of schooling, the presence of family history 
for dementia, the age at menopause, physiological or surgical 
menopause, reproductive life span, HRT intake, the presence 
of other pathologies, drug intake, and the premenopausal 
occurrence of reproductive system pathologies, ie, conditions 
in which significant differences between the AD patients and 
controls have been reported. The schooling level (P , 0.05) 
Table 2 Major reproductive life events in the AD and control patients
AD patients (275) Controls (276) Significance df P
Age at puberty # 10 23 16 3.323b 2 0.190
 11–15 227 243
 .15 25 17
Number of pregnancies (mean ± SD) 1.8 ± 1.3 1.9 ± 1.4 0.75b 1 0.39
Abortion (yes/no) 60/215 64/212 0.08b 1 0.777
Contraceptive therapy (yes/no) 8/267 15/261 1.611b 1 0.204
Age at menopause (,45) 69/206 95/181 5.298b 1 0.01
Menopause (physiological/surgical) 246/29 232/44 3.037b 1 0.04
hRT (yes/no) 6/269 32/244 17.568b 1 0.001
Reproductive life span (years, mean ± SD) 35.4 ± 4.4 34.5 ± 5.0 5.03b 1 0.01
Notes: aANOVA; bχ2 test.
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; hRT, hormone replacement therapy; df, degrees of freedom; ANOVA, analysis of variance.
Table 3 Presence of pathological conditions and their onset (pre-/postmenopause) in the AD and control patients (χ2 test)
AD patients  
(275)
Controls  
(276)
Significance df P
Arterial hypertension (yes) 
pre-/postmenopause
161 
12/149
151 
15/136
0.676 
0.333
1 
1
0.411 
0.564
Diabetes (yes) 
pre-/postmenopause
33 
7/26
31 
8/23
0.222  
0.019
1 
1
0.882 
0.890
Cardiovascular comorbidities (yes) 
pre-/postmenopause
148 
18/130
136 
24/112
0.964  
1.285
1 
1
0.326 
0.257
Thyroid pathologies (yes) 
pre-/postmenopause
28 
11/17
35 
10/25
0.222  
0.394
1 
1
0.637 
0.530
Obesity (yes) 
pre-/postmenopause
9 
6/3
16 
7/9
1.486  
0.468
1 
1
0.223 
0.494
Reproductive system pathologies (yes) 
pre-/postmenopause
31 
15/16
39 
30/9
0.773 
4.946
1 
1
0.379 
0.02
Psychiatric diseases (yes) 
pre-/postmenopause
77 
30/47
75 
25/50
0.015  
0.306
1 
1
0.903 
0.580
Other diseases (yes) 
pre-/postmenopause
72 
13/59
145 
38/107
38.981  
1.354
1 
1
0.0001 
0.245
Drug intake (yes) 
pre-/postmenopause
156 
41/113
210 
42/155
22.457 
1.069
1 
1
0.0001 
0.301
Abbreviations: AD, Alzheimer’s disease; df, degrees of freedom.
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and the presence of other pathologies (P , 0.01) were 
significantly higher in the control patients, thereby confirming 
their role in AD.
Discussion
The results of our study show that female controls went 
through menopause earlier and had a greater incidence of 
surgical menopause and reproductive-system pathologies 
before menopause than did women with AD; also, the 
reproductive life span was shorter. Moreover, the control 
patients were more likely to have taken HRT than were 
the AD patients. These findings are strictly related to each 
other; in particular, relationships were found between earlier 
menopause and HRT intake and between reproductive 
system pathologies occurring before menopause and surgical 
menopause. No significant differences were found between 
the AD patients and controls with respect to other reproductive 
life milestones, ie, age at puberty, previous abortions, number 
of pregnancies, and contraceptive therapy.
Our results suggest that among reproductive life events, 
only menopause and HRT intake distinguished the AD 
patients from the controls. These findings are in agreement 
with recent data showing a possible protective role for HRT. 
Some authors5,6,8–10 have hypothesized that a critical period 
around menopause exists during which the prescription of 
HRT might reduce the risk of developing AD at an older 
age. In our sample, a higher percentage of controls went 
through menopause before 45 years of age, as compared to 
AD patients; we can hypothesize that the control patients 
began HRT at an earlier age, with a possible protective effect. 
A higher risk of developing cognitive deficits following 
surgical menopause has been reported;13,17 conversely, we 
observed a higher incidence of surgical menopause in our 
control patients, but it is possible that their higher HRT intake 
protected these subjects from the dramatic estrogen loss that 
occurs following surgical menopause.
The control women also had a greater incidence of 
other pathologies (not known to be potential risk factors 
for dementia) and a higher drug intake than did the AD 
patients. In the multivariate analysis, only the presence of 
other pathologies was related to the lower risk of developing 
dementia, while no significant differences were found for 
drug intake, regardless of the type of drug. There was a 
relationship between drug intake and the presence of other 
pathologies (in fact, people with more pathologies generally 
take more drugs); however, it is difficult to explain how 
their relationship relates to the risk of developing AD. 
These results may be related to the type of enrollment 
(as explained below), with the control patients having greater 
recall than those with cognitive disease. It is noteworthy that 
we did not find any differences between the AD patients and 
the controls with respect to cardiovascular comorbidities or 
hypertension, which are factors capable of contributing to 
cognitive decline.
The multivariate analysis also showed that a higher level 
of education is related to a lower risk of developing AD. 
This relationship, irrespective of gender, has been clearly 
demonstrated in the literature.27,28 Education appears to have 
a protective effect on the development of AD; in addition 
to mentally and socially integrated lifestyles, education 
may postpone the onset of clinical dementia and therefore 
reduce its incidence.28 These data have been explained by the 
concept of a “cognitive reserve:” patients with a higher level 
of education have a greater cognitive reserve.28 Undoubtedly, 
an important limitation of our study is the type of enrollment. 
We designed this study to explore the reproductive life events 
preceding the onset of dementia, and the case-controlled 
approach was deemed useful for determining the relevance 
of these factors. We chose to enroll controls from among 
neurological outpatients to increase female participation 
and obtain a more selected population in terms of cognitive 
status. Another limitation may be the multicenter design, 
which nonetheless ensures control over geographical and 
ethnic variables. The controls’ mean age was lower for the 
Pavia clinic; however, the multivariate analysis excluded any 
predictive role for this factor.
Although we are aware that our results cannot be generalized 
to the entire population, nonetheless, to our knowledge, this is 
the first study in which all of the reproductive life events, not 
only menopause, were evaluated as potential factors capable 
of influencing the development of AD.
AD is a very complex, multifactorial disease. Besides 
genetic predisposition, which plays a major role, gender is 
an important factor in influencing disease susceptibility as 
well as disease evolution and outcomes.2,3,29,30 In women, 
menopause and HRT can differentially modulate the clinical 
manifestations of the disease, but they do not seem to have 
a predictive role in its development.
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